What do systematic reviews say?

Quinolone vs aminoglycosides

The review found no eligible studies for this question.

• Topical antibiotics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Sinonasal debridement vs no debridement

• Sinonasal debridement versus no debridement for the postoperative care of patients undergoing endoscopic sinus surgery 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 58 participants
  Low

Topical quinolone vs quinolones

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs intramuscular gentamicin

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs oral amoxicillin‐clavulanic acid combination

The review found no eligible studies for this question.

• Topical versus systemic antibiotics for chronic suppurative otitis media 2021 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs boric acid

The review found no eligible studies for this question.

• Antibiotics versus topical antiseptics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical quinolone vs povidone‐iodine

The review found no eligible studies for this question.

• Antibiotics versus topical antiseptics for chronic suppurative otitis media 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Topical antifungal vs placebo/no treatment

Topical antifungal may leads to lower heath‐related quality of life (HRQL) compared with placebo/no treatment (low certainty).

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  Low

Systemic antifungal vs placebo/no treatment

The review found no eligible studies for this question.

• Topical and systemic antifungal therapy for chronic rhinosinusitis 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Minimally invasive surgery vs Standard therapy alone (radiotherapy or chemoradiotherapy)

The review found no eligible studies for this question.

• Minimally invasive surgery versus radiotherapy/chemoradiotherapy for small‐volume primary oropharyngeal carcinoma 2016 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 38 participants
  Very low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 784 participants
  High

Anti‐IgE mAb (omalizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 265 participants
  Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 105 participants
  Low

Anti‐IL‐4Rα mAb (dupilumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 766 participants
  Moderate

Anti‐IL‐5 mAb (mepolizumab) vs placebo (on top of topical steroids)

• Biologics for chronic rhinosinusitis 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 105 participants
  Low

Intervention not reported

The intervention showed no clear difference in health‐related quality of life scores, measured by SF‐36 (range 0 to… (low certainty).

• Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps 2014 · Cochrane Headline outcomes only
  MD 0.6
  1 study · 95 participants
  Low